γδ T Cell Production via PTA-Induced Stem Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to efficiently induce stem cells with recombined γδ-TCR genes and produce γδ T cells due to the low abundance of TCRγδ-type T cells in peripheral blood, making it difficult to obtain sufficient numbers for cancer immunotherapy.
Innovation Solution
A method involving the application of tetrakis-pivaloyloxymethyl 2-(thiazol-2-ylamino) ethylidene-1, 1-bisphosphonate (PTA) and interleukins such as IL-2, IL-4, IL-9, IL-18, and IL-33, along with RNA virus vectors like Sendai virus, to induce pluripotent stem cells from blood or immune cells, followed by differentiation into γδ T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If methods are used to induce iPS cells with recombined γδ-TCR genes by reprogramming peripheral blood mononuclear cells stimulated by zoledronic acid, then stem cells with recombined γδ-TCR genes can be obtained, but the J1/J2 genes do not undergo recombination and the number of sufficient γδ T cells cannot be obtained
Solution Approach 1:
The invention changes the chemical parameters by replacing zoledronic acid with PTA (tetrakis-pivaloyloxymethyl-2-(thiazol-2-ylamino) ethylidene-1,1-bisphosphonate) and modifies the cytokine environment by adding IL-2, IL-4, IL-9, IL-18, and IL-33. These parameter changes enable both J1/J2 gene recombination and sufficient γδ T cell production from induced iPS cells
Solution Approach 2:
The invention introduces induced iPS cells as an intermediary between peripheral blood mononuclear cells and γδ T cells. This multi-step process allows genetic recombination to occur in the stem cell stage, which is then maintained through differentiation, ensuring both proper gene recombination and sufficient cell numbers for therapy
2Reliability
If TCRγδ-type T cells are obtained from peripheral blood, then cells with functional γδ-TCR can be obtained, but the low abundance (1-5%) makes it difficult to obtain sufficient numbers for cancer immunotherapy
Solution Approach 1:
The invention performs preliminary genetic recombination of γδ-TCR genes during the iPS cell induction stage, before differentiation. This preliminary action ensures that the genetic modification is established in the stem cell population, which is then amplified and maintained through subsequent differentiation into γδ T cells, achieving both functional expression and high productivity
3Ease of manufacture
If zoledronic acid is used to stimulate peripheral blood mononuclear cells, then iPS cells can be induced, but the γδ-TCR genes do not undergo complete recombination of J1/J2 genes
Solution Approach 1:
The invention changes the chemical stimulus from zoledronic acid to PTA and modifies the cytokine profile by adding IL-2, IL-4, IL-9, IL-18, and IL-33. These parameter changes create optimal conditions for complete V(D)J recombination of γδ-TCR genes including J1/J2 segments, while maintaining ease of iPS cell induction
Data Source
AI summary
According to the present disclosure, a method for producing stem cells is provided, comprising applying tetrakis-pivaloyloxymethyl 2-(thiazol-2-ylamino) ethylidene-1, 1-bisphosphonate (PTA) to blood cells or immune cells, and inducing stem cells from said blood cells or immune cells.